Pearl Therapeutics, Inc. clinical trials
Acquired by AstraZeneca, Jun 27, 2013 · source ↗
The registry lists 42 studies whose lead sponsor is Pearl Therapeutics, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 26, 2021.
- 42studies on the registry
- 0open to participants now
Before and after it joined AstraZeneca
- First submitted before Pearl Therapeutics, Inc. became part of AstraZeneca
- 13
- First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- 29
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Pearl Therapeutics, Inc.’s studies test, most studies first; none is open now — 8 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- Glycopyrrolate11 in phase 30 open · 19
- formoterol10 in phase 30 open · 13
- Budesonide5 in phase 30 open · 7
- 0 open · 6
- 0 open · 5
- PT0101 in phase 30 open · 4
- 0 open · 1
- 0 open · 1
All 42 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 08
- 09
- 10
- 11
- 12
- 13
- 14
- 1015
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Pearl Therapeutics, Inc.42 studies
Something wrong with this grouping? Tell us on the AstraZeneca page.
Studies
Recruiting first, then most recently updated. Showing 42 of 42. All AstraZeneca studies →
- Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseCompletedNCT02536508Phase 3
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)CompletedNCT02465567Phase 3
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat DoseCompletedNCT03250182Phase 1
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult SubjectsCompletedNCT03075267Phase 1
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)CompletedNCT02497001Phase 3
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPDCompletedNCT02109406Phase 2
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant AsthmaCompletedNCT03358147Phase 2/3
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010CompletedNCT03311373Phase 1
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®CompletedNCT03262012Phase 3
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)CompletedNCT02727660Phase 3
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPDCompletedNCT02766608Phase 3
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPDTerminatedNCT02685293Phase 3
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPDCompletedNCT02937584Phase 3
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPDCompletedNCT02643082Phase 3
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPDCompletedNCT02343458Phase 3
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary DiseaseWithdrawnNCT03081247Phase 3
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- 24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDICompletedNCT02347085Phase 3
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01350128Phase 2
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted before Pearl Therapeutics, Inc. became part of AstraZeneca
- Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02196077Phase 2
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- Pharmacokinetics and Safety Study of PT010 in Healthy SubjectsCompletedNCT02189304Phase 1
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPDCompletedNCT03256552Phase 2
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPDCompletedNCT01566773Phase 2
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted before Pearl Therapeutics, Inc. became part of AstraZeneca
- Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent AsthmaCompletedNCT02433834Phase 2
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent AsthmaCompletedNCT02105012Phase 2
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- PT003 MDI Dose Confirmation StudyCompletedNCT01349816Phase 2
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted before Pearl Therapeutics, Inc. became part of AstraZeneca
- PK Study of PT003 and PT001 in Japanese Healthy SubjectsCompletedNCT02196714Phase 1
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy SubjectsCompletedNCT00893971Phase 1
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted before Pearl Therapeutics, Inc. became part of AstraZeneca
- Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01085045Phase 2
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted before Pearl Therapeutics, Inc. became part of AstraZeneca
- 24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and PlaceboCompletedNCT02347072Phase 3
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPDCompletedNCT02454959Phase 3
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)CompletedNCT01854658Phase 3
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted before Pearl Therapeutics, Inc. became part of AstraZeneca
- Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)CompletedNCT01854645Phase 3
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted before Pearl Therapeutics, Inc. became part of AstraZeneca
- Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)CompletedNCT01970878Phase 3
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- PT003 MDI Cardiovascular Safety StudyCompletedNCT01349803Phase 2
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted before Pearl Therapeutics, Inc. became part of AstraZeneca
- Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPDCompletedNCT02268396Phase 3
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCompletedNCT01587079Phase 2
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted before Pearl Therapeutics, Inc. became part of AstraZeneca
- Randomized, Crossover Safety and Pharmacokinetics Study of PT010CompletedNCT02197975Phase 1
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active ControlWithdrawnNCT01043601Phase 2
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted before Pearl Therapeutics, Inc. became part of AstraZeneca
- Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy VolunteersCompletedNCT01980615Phase 1
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted after Pearl Therapeutics, Inc. became part of AstraZeneca
- Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00871182Phase 1/2
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted before Pearl Therapeutics, Inc. became part of AstraZeneca
- PT005 MDI Dose Ranging Versus Foradil Aerolizer StudyCompletedNCT01349868Phase 2
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted before Pearl Therapeutics, Inc. became part of AstraZeneca
- Study to Evaluate the Safety and Efficacy of Inhaled PT005 in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00880490Phase 1/2
Sponsor listed in the registry: Pearl Therapeutics, Inc. · First submitted before Pearl Therapeutics, Inc. became part of AstraZeneca